⚠ Ion Placements Fell 28% in the Year Its Procedures Grew 51%Moderate threat

Intuitive Surgical (ISRG) — threat to the moat

A second franchise being used harder by its adopters and adopted more slowly by everyone else.

The Ion numbers pull in two directions and the divergence is worth understanding.

Two Ion numbers pointing opposite waysProcedure growth, 2025About 51%, to 144,100Procedure growth, Q2 202636%Placements, 2025 against 2024195 against 271, down 28%Placements, Q2 2026 against Q2 202555 against 54A bronchoscopy suite needs fewer systems than an operating theatre complex.
The benign reading is that early adopters are ramping. The less comfortable one is that a diagnostic indication is a narrower proposition than a therapeutic one.

Procedures grew approximately 51% in 2025 to about 144,100, and 36% in the June 2026 quarter1. Placements went the other way: 195 systems in 2025 against 271 in 2024, a fall of 28%2. In the June quarter placements were 55 against 54 — essentially flat3.

The benign reading is that Ion's early adopters are ramping fast, that a bronchoscopy suite needs fewer systems than an operating theatre complex, and that the capital environment for a second robotic platform is harder than for the first. Intuitive's own language about China is "a measured fashion"4, and it has described the broader rollout in similar terms.

The less comfortable reading is that Ion faces a narrower value proposition than da Vinci. Its indication is diagnostic rather than therapeutic, the alternative — conventional bronchoscopy with fluoroscopic or electromagnetic navigation — is cheaper, and a hospital buying one is buying a second robotics programme with its own training requirement. Noah Medical appears in Intuitive's competition list5 specifically in this space.

The regulatory extension of catheter uses from five to eight6 also cut the consumable revenue per procedure at exactly the moment the franchise was scaling.

Watch placements rather than procedures. Procedures growing on a flat base is utilisation, which is finite; it is placements that say whether the second franchise is still being adopted.

References
  1. ReportedProcedures grew approximately 51% in 2025 to about 144,100, and 36% in the June 2026 quarter.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  2. ReportedPlacements went the other way: 195 systems in 2025 against 271 in 2024, a fall of 28%.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedIn the June quarter placements were 55 against 54 — essentially flat.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  4. ReportedIntuitive's own language about China is "a measured fashion", and it has described the broader rollout in similar terms.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedNoah Medical appears in Intuitive's competition list specifically in this space.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  6. ReportedThe regulatory extension of catheter uses from five to eight also cut the consumable revenue per procedure at exactly the moment the franchise was scaling.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
Sources
Generated September 23, 2026